Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone978-600-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$563.82 million
Profitability
Miscellaneous
Employees1,169
Next Earnings Date11/5/2019 (Confirmed)
OptionableOptionable
Insulet (NASDAQ:PODD) Frequently Asked Questions
What is Insulet's stock symbol?
Insulet trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet's earnings last quarter?
Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Monday, August, 5th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.01. The medical instruments supplier had revenue of $177.10 million for the quarter, compared to the consensus estimate of $163.63 million. Insulet had a return on equity of 7.85% and a net margin of 2.66%. The business's revenue for the quarter was up 42.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.03) earnings per share. View Insulet's Earnings History.
When is Insulet's next earnings date?
How can I listen to Insulet's earnings call?
Insulet will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Insulet issued on next quarter's earnings?
Insulet issued an update on its third quarter 2019 earnings guidance on Monday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $174-181 million, compared to the consensus revenue estimate of $172.7 million.
What price target have analysts set for PODD?
15 Wall Street analysts have issued 12 month price objectives for Insulet's stock. Their predictions range from $100.00 to $185.00. On average, they anticipate Insulet's share price to reach $145.36 in the next twelve months. This suggests that the stock has a possible downside of 3.7%. View Analyst Price Targets for Insulet.
What is the consensus analysts' recommendation for Insulet?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.
Has Insulet been receiving favorable news coverage?
Press coverage about PODD stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Insulet earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Insulet.
Are investors shorting Insulet?
Insulet saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,710,000 shares, an increase of 13.8% from the August 30th total of 4,140,000 shares. Based on an average daily volume of 903,900 shares, the short-interest ratio is presently 5.2 days. Approximately 7.9% of the shares of the stock are sold short. View Insulet's Current Options Chain.
Who are some of Insulet's key competitors?
Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).
What other stocks do shareholders of Insulet own?
Who are Insulet's key executives?
Insulet's management team includes the folowing people:
- Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
- Mr. Charles Alpuche, Exec. VP & COO (Age 59)
- Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
- Mr. Patrick J. Sullivan, Consultant (Age 67)
- Mr. Michael L. Levitz, Advisor (Age 45)
Who are Insulet's major shareholders?
Insulet's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include KAMES CAPITAL plc (0.62%), Stephens Investment Management Group LLC (0.26%), Envestnet Asset Management Inc. (0.04%), CIBC Private Wealth Group LLC (0.02%), Gradient Investments LLC (0.02%) and Handelsinvest Investeringsforvaltning (0.01%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.
Which institutional investors are selling Insulet stock?
PODD stock was sold by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, CIBC Private Wealth Group LLC, Stephens Inc. AR and Strs Ohio. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.
Which institutional investors are buying Insulet stock?
PODD stock was bought by a variety of institutional investors in the last quarter, including Stephens Investment Management Group LLC, Handelsinvest Investeringsforvaltning, First Citizens Bank & Trust Co., First Hawaiian Bank, Envestnet Asset Management Inc., Meeder Asset Management Inc., Cerebellum GP LLC and Juncture Wealth Strategies LLC. View Insider Buying and Selling for Insulet.
How do I buy shares of Insulet?
Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Insulet's stock price today?
One share of PODD stock can currently be purchased for approximately $150.87.
How big of a company is Insulet?
Insulet has a market capitalization of $9.09 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.
What is Insulet's official website?
How can I contact Insulet?
Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]
MarketBeat Community Rating for Insulet (NASDAQ PODD)
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
